Incyte
Focus: Incyte is a mid-cap biotech focused on small-molecule therapies in oncology and immunology, headquartered in Wilmington, DE. The company is heavily dependent on its flagship JAK inhibitor franchise, particularly JAKAFI.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Incyte
AI assessmentNot HiringNo open roles listed right now. Follow Incyte to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Incyte's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
1 in 5yr
JAKAFI
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$1.9B Part DDeclining
LOE Approaching
Help build intelligence for Incyte
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.